Rakesh Bhattacharjee1, Abdelnaby Khalyfa2, Ahamed A Khalyfa2, Babak Mokhlesi3, Leila Kheirandish-Gozal2, Isaac Almendros4, Eduard Peris2, Atul Malhotra5, David Gozal2. 1. Division of Respiratory Medicine, Department of Pediatrics, Rady Children's Hospital, The University of California San Diego, San Diego, California. 2. Section of Sleep Medicine, Department of Pediatrics, Pritzker School of Medicine, Biological Sciences Division University of Chicago, Chicago, Illinois. 3. Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, Illinois. 4. Universitat of Barcelona/IDIBAPS-CIBERES, Barcelona, Spain. 5. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego, San Diego, California.
Abstract
STUDY OBJECTIVES: Longitudinal studies support the usage of positive airway pressure (PAP) therapy in treating obstructive sleep apnea (OSA) to improve cardiovascular disease. However, the anticipated benefit is not ubiquitous. In this study, we elucidate whether PAP therapy leads to immediate improvements on endothelial function, a subclinical marker of cardiovascular status, by examining the effect of circulating exosomes, isolated from patients before and after PAP therapy, on naive endothelial cells. METHODS: We isolated plasma-derived circulating exosomes from 12 patients with severe OSA and obesity hypoventilation syndrome (OHS) before and after 6 weeks of PAP therapy, and examined their effect on cultured endothelial cells using several in vitro reporter assays. RESULTS: We found that circulating exosomes contributed to the induction and propagation of OSA/OHS-related endothelial dysfunction (ie, increased permeability and disruption of tight junctions along with increased adhesion molecule expression, and reduced endothelial nitric oxide synthase expression), and promoted increased monocyte adherence. Further, when comparing exosomes isolated before and after PAP therapy, the disturbances in endothelial cell function were attenuated with treatment, including an overall cumulative decrease in endothelial permeability in all 12 subjects by 10.8% (P = .035), as well as detection of a subset of 4 differentially expressed exosomal miRNAs, even in the absence of parallel changes in systemic blood pressure or metabolic function. CONCLUSIONS: Circulating exosomes facilitate important intercellular signals that modify endothelial phenotype, and thus emerge as potential fundamental contributors in the context of OSA/OHS-related endothelial dysfunction. Exosomes may not only provide candidate biomarkers, but are also a likely and plausible mechanism toward OSA/OHS-induced cardiovascular disease. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov, Title: AVAPS-AE Efficacy Study, URL: https://clinicaltrials.gov/ct2/show/NCT01368614, Identifier: NCT01368614.
STUDY OBJECTIVES: Longitudinal studies support the usage of positive airway pressure (PAP) therapy in treating obstructive sleep apnea (OSA) to improve cardiovascular disease. However, the anticipated benefit is not ubiquitous. In this study, we elucidate whether PAP therapy leads to immediate improvements on endothelial function, a subclinical marker of cardiovascular status, by examining the effect of circulating exosomes, isolated from patients before and after PAP therapy, on naive endothelial cells. METHODS: We isolated plasma-derived circulating exosomes from 12 patients with severe OSA and obesity hypoventilation syndrome (OHS) before and after 6 weeks of PAP therapy, and examined their effect on cultured endothelial cells using several in vitro reporter assays. RESULTS: We found that circulating exosomes contributed to the induction and propagation of OSA/OHS-related endothelial dysfunction (ie, increased permeability and disruption of tight junctions along with increased adhesion molecule expression, and reduced endothelial nitric oxide synthase expression), and promoted increased monocyte adherence. Further, when comparing exosomes isolated before and after PAP therapy, the disturbances in endothelial cell function were attenuated with treatment, including an overall cumulative decrease in endothelial permeability in all 12 subjects by 10.8% (P = .035), as well as detection of a subset of 4 differentially expressed exosomal miRNAs, even in the absence of parallel changes in systemic blood pressure or metabolic function. CONCLUSIONS: Circulating exosomes facilitate important intercellular signals that modify endothelial phenotype, and thus emerge as potential fundamental contributors in the context of OSA/OHS-related endothelial dysfunction. Exosomes may not only provide candidate biomarkers, but are also a likely and plausible mechanism toward OSA/OHS-induced cardiovascular disease. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov, Title: AVAPS-AE Efficacy Study, URL: https://clinicaltrials.gov/ct2/show/NCT01368614, Identifier: NCT01368614.
Authors: Abdelnaby Khalyfa; Chunling Zhang; Ahamed A Khalyfa; Glen E Foster; Andrew E Beaudin; Jorge Andrade; Patrick J Hanly; Marc J Poulin; David Gozal Journal: Sleep Date: 2016-12-01 Impact factor: 5.849
Authors: Michael Arzt; Terry Young; Laurel Finn; James B Skatrud; T Douglas Bradley Journal: Am J Respir Crit Care Med Date: 2005-09-01 Impact factor: 21.405
Authors: Philipp Diehl; Alba Fricke; Laura Sander; Johannes Stamm; Nicole Bassler; Nay Htun; Mark Ziemann; Thomas Helbing; Assam El-Osta; Jeremy B M Jowett; Karlheinz Peter Journal: Cardiovasc Res Date: 2012-01-18 Impact factor: 10.787
Authors: Olalla Castro-Añón; Luis A Pérez de Llano; Sandra De la Fuente Sánchez; Rafael Golpe; Lidia Méndez Marote; Julián Castro-Castro; Arturo González Quintela Journal: PLoS One Date: 2015-02-11 Impact factor: 3.240
Authors: Atul Malhotra; Indu Ayappa; Najib Ayas; Nancy Collop; Douglas Kirsch; Nigel Mcardle; Reena Mehra; Allan I Pack; Naresh Punjabi; David P White; Daniel J Gottlieb Journal: Sleep Date: 2021-07-09 Impact factor: 6.313
Authors: Jakub Mochol; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Helena Martynowicz; Adrian Doroszko Journal: Int J Mol Sci Date: 2021-05-12 Impact factor: 5.923